Background: Among the numerous human papillomavirus (HPV) types, only types 16 and 18 have been formally classified as human carcinogens. To evaluate the associations of 33 HPV types and other risk factors with squamous cell carcinoma and adenocarcinoma of the cervix, we performed a hospital-based, case-control study in the Philippines. Methods: The study included 356 case subjects who had histologically confirmed cervical cancer (323 incident cases of squamous cell carcinoma and 33 incident cases of adenocarcinoma/adenosquamous carcinoma) and 381 control subjects. Information on risk factors was obtained by personal interview. HPV DNA was detected in exfoliated cervical cells and biopsy specimens by use of a polymerase chain reaction assay. Results: HPV DNA was detected in 93.8% of case subjects with squamous cell carcinoma and in 90.9% of case subjects with adenocarcinoma/adenosquamous carcinoma compared with 9.2% of control subjects, giving age-adjusted odds ratios of 156 (95% confidence interval [CI] = 87-280) for squamous cell carcinoma and 111 (95% CI = 31-392) for adenocarcinoma/adenosquamous carcinoma. Fifteen different HPV types were detected in squamous cell carcinoma, and six different HPV types were detected in adenocarcinoma/ adenosquamous carcinoma. Among HPV types other than types 16 and 18, the associations of HPV with risk of squamous cell carcinoma were strongest for HPV45. In addition to HPV, high parity, low socioeconomic status,
Certain types of human papillomavirus (HPV) are currently recognized as the central etiologic factor of invasive cervical cancer (1, 2) and of its precursor lesions (3) (4) (5) . In 1995, the International Agency for Research on Cancer (IARC) (6) evaluated all relevant data on the carcinogenicity of HPV and concluded that there was sufficient evidence to categorize HPV types 16 and 18 as human carcinogens but that the existing evidence was limited or inadequate for the other HPV types. At that time, odds ratios (ORs) for HPV types 31, 33, and 35 and invasive cervical carcinoma had been reported for only the three types as a group from case-control studies in Spain and Colombia (1, 3) and in Brazil (2) . Since the IARC evaluation, we have completed case-control studies in other populations in which standard protocols and questionnaires were employed. A polymerase chain reaction (PCR)-based assay capable of detecting 33 HPV types was used (7, 8) , and ORs for the most common HPV types were estimated for both squamous cell carcinomas and adenocarcinomas. The role of other risk factors after controlling for the strong effect of HPV has been examined in a few studies (1) (2) (3) .
We report here the main results of a hospital-based, case-control study conducted in Manila, the Philippines, which has a population with intermediate rates for cervical cancer (age-adjusted incidence rate 25 per 100 000) (9) .
Patients and Methods

Study Population
From April 1991 through April 1993, 387 consecutive women with a diagnosis of invasive cervical cancer and 392 control women were identified from the outpatient clinics and wards of the Philippine General Hospital in Manila. Inclusion criteria for case subjects were that they had a histologically confirmed cervical cancer (incident case of squamous cell carcinoma or adenocarcinoma/adenosquamous carcinoma) and had not received any treatment. The histologic slides in which the diagnosis was made were reviewed by an expert pathologist (M. Santamaria). Control women were selected to match the expected age distribution of the case subjects and had to fulfill the following inclusion criteria: not to have had conization, hysterectomy, or diseases associated with known risk factors for cervical neoplasia (other anogenital tumors and tumors of the breast, oral cavity, esophagus, lung, bladder, and liver; cardiovascular or cerebrovascular diseases; chronic bronchitis; or emphysema). Evidence of cytologic abnormality detected on examination after recruitment was not a criterion for exclusion. Case and control subjects who were in poor physical or mental condition were excluded.
All eligible case subjects and 387 (98.7%) of 392 eligible control subjects agreed to participate and provided biologic specimens.
The cytologic diagnoses of the control subjects at entry into the study were as follows: normal (n ‫ס‬ 277), inflammatory (n ‫ס‬ 84), low-grade squamous intraepithelial lesion (n ‫ס‬ 6), high-grade squamous intraepithelial lesion (n ‫ס‬ 3), and inadequate for diagnosis (n ‫ס‬ 12).
The main diagnostic categories of the control subjects included in the study were urinary infections (n ‫ס‬ 75), benign disorders of the genital tract (n ‫ס‬ 53), menstrual disorders (n ‫ס‬ 43), diseases of the circulatory system (n ‫ס‬ 31), mild mental disorders (n ‫ס‬ 28), endocrine or metabolic disease (n ‫ס‬ 18), diseases of the respiratory system (n ‫ס‬ 16), diseases of the nervous systems (n ‫ס‬ 14), diseases of the musculoskeletal system (n ‫ס‬ 14), diseases of the digestive system (n ‫ס‬ 9), diseases of the skin (n ‫ס‬ 9), infectious or parasitic disease (n ‫ס‬ 8), and other diseases (n ‫ס‬ 12). In addition, 57 healthy women who were visiting the hospital for reasons other than illness (usually accompanying outpatients) were included as control subjects.
After histologic review, the cancers in the case subjects were classified as follows: squamous cell carcinoma (n ‫ס‬ 344), adenocarcinoma (n ‫ס‬ 23), adenosquamous carcinoma (n ‫ס‬ 11), and clear cell carcinoma (n ‫ס‬ 3); histologic slides were not available for six case subjects. Two main groups of carcinoma were considered for the analysis by histologic type: squamous cell carcinoma and adenocarcinoma/adenosquamous carcinoma. The squamous cell carcinomas were further categorized into the following subtypes: keratinizing large cells (2.4%), nonkeratinizing large cells (94.2%), nonkeratinizing small cells (0.5%), and others (2.9%).
Information on clinical stage was available for 371 (96%) of the case subjects. The stages (10) were distributed as follows: stage I, 62 case subjects (17%); stage II, 136 case subjects (37%); stage III, 170 case subjects (46%); and stage IV, three case subjects (0.01%).
Data and Specimen Collection
Study subjects were interviewed at the hospital by use of a standardized questionnaire to elicit information on sexual behavior, reproductive history, contraceptive practice, smoking habits, genital hygiene, history of sexually transmitted diseases, screening history, and various measures of socioeconomic status (e.g., education, occupation, income per capita, type of housing, and household facilities). Three specially trained female technicians administered the interview to all case and control subjects. An effort was made to keep them blinded to the case or control status of the study subjects. The average time taken to complete the interview was 23 minutes. After the interview, all women had a pelvic examination performed by a gynecologist, who also took two cervical scrapes with an Ayre spatula and an endocervical brush. One Pap smear was prepared, and the remaining cells were eluted in phosphate-buffered saline (PBS), pelleted in PBS (2000 rpm for 10 minutes at room temperature), and kept at −70°C for later use for HPV DNA detection. A tumor biopsy specimen was also taken in most cases and kept frozen for virologic studies. A 10-mL blood sample was also collected from all women for the detection of antibodies to certain sexually transmitted agents.
The study protocol was cleared by the ethical committee of the International Agency for Research on Cancer and by local ethical committees. Written informed consent was obtained from the study subjects.
HPV DNA Detection and Typing
HPV DNA detection in cervical scrapes was performed by PCR (7, 8) . To analyze the quality of target DNA for PCR purposes, we prescreened specimens by PCR with the use of ␤-globin gene-specific oligonucleotide primers (11) . Specimens that showed successful amplification of ␤-globin sequences were subjected to HPV DNA genotyping.
The genotyping was carried out as follows: Briefly, a first screening to determine the overall presence of HPV was performed by use of a general primer GP5+/6+-mediated PCR, which permits the detection of a broad spectrum of sequenced and stillunsequenced genital HPV types at the subpicogram level (7) . HPV positivity was assessed by lowstringency Southern blot analysis of PCR products with a cocktail probe of HPV-specific DNA fragments (12) . Subsequently, GP5+/6+ PCR was repeated in triplicate on positive samples to generate sufficient products for further typing. PCR products from independent reactions were pooled to generate 11 identical Southern blots for parallel and successive hybridization rounds for typing with the use of internal type-specific oligoprobes (8) . The strategy of melting and rehybridization of the filters was essentially the same as that described earlier (13 (12, 13) . Type-specific oligonucleotides (30-mers) were selected on the basis of sequence information from the HPV sequence database (14, 15) after alignment analysis with the CLUSTAL program (PC/Gene Release 6.7; Intelligenetics, Inc., Mountain View, CA) (16) .
In a second step, for those specimens found to be ␤-globin PCR negative as well as HPV PCR negative, DNA was extracted from the cell pellets and retested for HPV DNA as described above. In addition, for those cases for which not enough cell pellet was available as well as for those cases testing negative for HPV in the exfoliated cells, the HPV DNA analysis was done on the corresponding biopsy specimens of these carcinomas. For HPV detection in the biopsy specimen, the sandwich method was used as described earlier (17) . Briefly, snap-frozen tissues were cut in a way that the outer sections of a series of sections were used for histologic analysis, and the inner sections were used for PCR testing.
The special precautions we took to minimize false-positive results in the PCR have been described in detail elsewhere (12) .
Only those specimens found to be ␤-globin PCR positive or negative and HPV DNA positive were included in the analysis. Thus, 22 (5%) case subjects and six (1.5%) control subjects classified as negative for ␤-globin and HPV DNA were excluded, which left 365 case subjects and 381 control subjects. In addition, six case subjects for whom the histologic diagnosis was not confirmed and three who had a diagnosis of clear cell carcinoma were also excluded, which left a final total of 356 case subjects.
For case subjects, the combined prevalence of HPV DNA (detected in exfoliated cells and in biopsy specimens) is given. For control subjects, the HPV DNA prevalence was detected only in exfoliated cells.
Statistical Analysis
To estimate the risk of cervical cancer associated with various HPV types and the other risk factors, we calculated odds ratios (ORs) and 95% confidence intervals (CIs) as approximations of relative risks by using unconditional logistic regression (18) . The ORs for HPV were adjusted only for age (categorized in four age groups: <40 years, 40-49 years, 50-59 years, and ജ60 years). ORs for other risk factors are given, adjusted for age and for age, HPV, and all variables included in the final model. In an attempt to identify factors that influence the progression from HPV carrier state to invasive carcinoma, we used a model that was restricted to HPV-positive case and control subjects and that included all variables being evaluated.
We examined various measures of socioeconomic status: place of residence, educational level, occupation, housing characteristics, and number of household amenities (i.e., television, refrigerator, and toilet and running water inside the house). Educational level and household amenities showed the strongest associations with risk, but only the latter was included in the final multivariate analysis.
Statistical significance was tested by use of the likelihood ratio test for the difference for dichotomous variables and for two-sided linear trend for variables with logically ordered categories.
From the variables that were highly correlated (with the use of Pearson's correlation coefficients) and that may have been measuring the same effect, one was selected for inclusion in the final model; i.e., age at first intercourse that was highly correlated with age at first marriage and age at first pregnancy (correlation coefficients ‫ס‬ .97 and .84, respectively) was included in the final model.
HPV attributable fractions (AFs) have been calculated according to standard methods, AF ‫ס‬ p(r − 1)/[1 + p(r − 1)], where p ‫ס‬ HPV DNA prevalence in the population approximated by the prevalence in the control group and r ‫ס‬ relative risk approximated by the OR.
Some deviations from the protocol could have introduced biases in the selection of control subjects. The design was hospital based, but 57 control subjects were healthy women who were visiting the hospital for reasons other than illness, usually accompanying a sick relative. In addition, 53 women with benign disorders of the genital tract, who were ineligible according to our protocol, were included. However, the exposures to the risk factors under study of these two groups of women were compared with those of the other hospital control subjects, and no significant differences were found. Moreover, the prevalence of cytologic abnormalities and HPV positivity in these two groups was very similar to that of the whole group of control subjects. Finally, excluding these two groups of women from the analyses had little effect on the adjusted risk estimates for HPV and other risk factors; therefore, they were included in the final analyses.
Results
For patients with squamous cell carcinoma, the mean age was 47.2 years; for those with adenocarcinoma/adenosquamous carcinoma, it was 48.4 years; for control subjects, it was 46.8 years. Table 1 summarizes the HPV DNA prevalence in case and control subjects.
Among control subjects, the HPV DNA prevalence in exfoliated cells was 9.2%. It increased with the number of sexual partners and was lower among women starting sexual intercourse under 20 years of age, but the tests for trend were not statistically significant. However, the HPV DNA prevalence did not show a clear trend with age or education. Among case subjects, the HPV DNA prevalence among case subjects did not vary with any of the variables considered (data not shown).
Fifteen different HPV types were detected among the patients with squamous cell carcinoma, five among the patients with adenocarcinoma/adenosquamous carcinoma, and 17 among the control subjects. HPV types 6, 11, 26, 33, 34, 35, 40, 42, 43, 44, 54, 57, 61, MM7, and CP4173 were not identified in any of the tumor specimens from patients with squamous cell carcinoma ( Table 1) .
The most common HPV type in women with squamous cell carcinoma was HPV type 16 followed by HPV types 18, 45, 52, and 51; in women with adenocarcinoma/adenosquamous carcinoma, HPV type 18 was the most common type followed by types 16 and 45.
HPV type 45 was the most common type in control women followed by HPV types 16 and 18.
Two or more different HPV types were detected in 25 (7.7%) of the women with squamous cell carcinoma, in five (15.2%) of the women with adenocarcinoma/ adenosquamous carcinoma, and in five (1.3%) of the control subjects; these are counted twice or more in Table 2 . Thirtytwo (9.9%) specimens from patients with squamous cell carcinoma, two (6.1%) from patients with adenocarcinoma/ adenosquamous carcinoma, and five (1.3%) from control women had HPVs that could not be typed with the 33 typespecific probes that we used and were classified as HPV X. The age-adjusted ORs for the most common HPV types (those detected in at least four case subjects) are given in Table 2 . For any HPV, the age-adjusted OR for squamous cell carcinoma was 156 and the AF was 93.5%; for adenocarcinoma/adenosquamous carcinoma, the OR was 111 and the AF was 91%.
For both squamous cell carcinoma and adenocarcinoma/adenosquamous carcinoma, very high ORs were observed with the various HPV types. In squamous cell carcinoma, they ranged from 81 for HPV58 to 506 for HPV16; in adenocarcinoma/adenosquamous carcinoma, they ranged from 259 for HPV45 to 948 for HPV18.
The association of cervical cancer risk with HPV66 cannot be properly assessed because it was detected only as coinfection with other high-risk HPV types. Table 3 summarizes the association of †Beginning with the fourth value in this column (i.e., 8.6), all percentages reflect the percent of HPV-positive control subjects. squamous cell carcinoma with risk factors other than HPV. After adjustment for age, HPV, and all factors shown in the table, the following factors were significantly related to risk: number of household amenities (P for trend ‫ס‬ .003), smoking (P for trend ‫ס‬ .001), and parity and age at first intercourse (borderline significance, P for trend ‫ס‬ .07). With regard to smoking, a statistically significant increase in risk was observed with years of smoking and numbers of cigarettes smoked per day (data not shown). The effect of number of sexual partners decreased and became nonsignificant after adjustment for HPV (P for trend ‫ס‬ .7). There was a strong protective effect with the interval since the last Pap smear (P for trend ‫ס‬ .001). When a similar analysis was performed and was restricted to HPV-positive women only, similar associations were observed, but the tests for trend were statistically significant only for parity and interval since last Pap smear (P ‫ס‬ .05 and .001, respectively). Table 4 shows similar analyses for adenocarcinoma/adenosquamous carcinoma. After adjustment for age, HPV, and other factors included in the table, statistically significant associations were observed for number of household amenities (P for trend ‫ס‬ .005), parity (P for trend ‫ס‬ .03), and interval since last Pap smear (P for trend ‫ס‬ .04). Among HPVpositive women, similar associations were observed, but only number of household amenities showed a statistically significant trend (P ‫ס‬ .02).
Discussion
Of the 75 HPV types that have been cloned to date, at least 30 are known to infect the genital tract and 18 of them have been detected in frozen biopsy specimens from about 1000 women from 22 countries who have been diagnosed with invasive cervical cancer (19) . Although experimental and some epidemiologic evidence suggests that these types are carcinogenic, an estimation of the risk of developing cervical cancer linked to these HPV types can be derived only from case-control studies. In 1995, an IARC working group (6) evaluated the carcinogenicity of HPV types and concluded that only HPV16 and HPV18 could be classified as human carcinogens; other HPV genital types were classified as probable or possible carcinogens because the epidemiologic evidence available at that time was limited or inadequate.
By the application of the HPV general primer GP5+/6+-mediated PCR in combination with HPV type-specific oligoprobes, most, if not all, genital HPVs can be detected (7, 8) . The strategy used for typing in this study has been tested before (13) , and it has been shown that three rounds of melting and rehybridization of the filters do not affect the sensitivity of the assay. Therefore, eventual underrepresentations of HPV types tested in this study are unlikely to be the result of the typing methodology. Using this methodology, we report here the results of a case-control study conducted in the Philippines in which the risk for the seven HPV types more common in this population (HPV types 16, 18, 45, 51, 52, 58, and 59) was estimated. In addition, we were able to estimate the risk linked to some of these HPV types for the two main histologic types of cervical cancer: squamous cell carcinoma and adenocarcinoma/adenosquamous carcinoma. For both histologic types, a very strong association was observed for the presence of HPV DNA; the ageadjusted OR for squamous cell carcinoma was 156 and that for adenocarcinoma/ adenosquamous carcinoma was 111. HPV16 was the most common type in squamous cell carcinoma (43% of the positives), followed by HPV18 (25%) and HPV45 (14%). In specimens of adenocarcinoma/adenosquamous carcinoma, HPV18 was the predominant type (57%), followed by HPV16 (27%) and HPV45 (17%). These distributions are similar to those reported in the IARC international survey of HPV types in invasive cervical cancer (19) , with the exception of HPV types 33 and 35 that were not detected in our study population. However, these two types were also rare in the specimens from Southeast Asia included in our international survey; their prevalences were 2% and 1%, respectively. Among control subjects, the three most common types of HPV were also the most commonly detected in cervical cancer, i.e., HPV types 16, 18, and 45, which has also been the case in our previous casecontrol studies in Colombia and Spain (1, 3) It can be argued that these ORs have been artificially increased because those case subjects whose exfoliated cells were negative for HPV were tested again by use of the biopsy specimens, whereas the exfoliated cells of the control subjects were tested only once. However, several observations justify the use of two types of biologic specimens in case subjects and one in control subjects. Our unpublished results from further testing of the specimens originally classified as negative in the IARC international survey of HPV types in invasive cervical cancer indicate that the true prevalence of HPV in these cancers is at least 99%. Concerning the HPV prevalence among control subjects, preliminary results from our ongoing study comparing the HPV prevalence in exfoliated cells with that detected in biopsy specimens taken from women without cervical neoplasia who were undergoing hysterectomy for various reasons indicate that the HPV prevalence is very similar in the two types of specimens. This result suggests that the use of only exfoliated cells in the control subjects does not underestimate the prevalence of HPV DNA.
The prevalence in the group of control subjects in the Philippines (9%) is lower than that reported in the control subjects in a study from Brazil (17%) in which the GP5/6 PCR-based assay was used (2) . This result correlates well with the risk of cervical cancer in these two populations [age-adjusted incidence rate ‫ס‬ 20 per 100 000 in Manila and 35 per 100 000 in São Paulo, Brazil (9)].
Although several case series in which PCR-based assays were used have reported a prevalence of HPV DNA ranging from 25% to 96% in adenocarcinoma (6) , no formal case-control studies have been reported. To our knowledge, this is the first case-control study in which the risk linked to specific HPV types has been estimated for adenocarcinoma/adenosquamous carcinoma. Our results confirm that, as was found for squamous cell carcinoma, certain HPV types are the main cause of adenocarcinoma/adenosquamous carcinoma.
The main implications of our HPV findings are as follows: 1) In addition to HPV types 16 and 18, HPV types 45, 51, 52, 58, and 59 can now be considered to be carcinogenic for humans, if we follow the criteria used for the IARC monograph to evaluate the carcinogenicity. 2) HPV types 16, 18 , and 45 are the main cause of adenocarcinoma/adenosquamous carcinoma in the Philippines.
3) The classification of HPV into high-risk, intermediate-risk, and low-risk types, as proposed a few years ago by Lörincz et al. (20) , based on the magnitude of the ORs should be revised.
Few independent risk factors were identified in addition to the strong effect of HPV. For squamous cell carcinoma, high parity, number of household amenities (as a surrogate of socioeconomic status), and interval since last Pap smear were significantly associated with risk. Similar associations have been observed in our studies in Spain and Colombia (1, 3, 21) , Brazil (2), and Morocco (22) but not in Thailand (23) . Although an association of risk of squamous cell carcinoma with early age at first intercourse was observed, it was not statistically significant. The statistically significant association of risk of squamous cell carcinoma with smoking is intriguing in this population in which the prevalence of smokers is very low (21% of the case subjects and 8% of the control subjects were ever smokers). No clear association of risk of squamous cell carcinoma with smoking was observed in our previous studies in Spain, Colombia, Brazil, Morocco, and Thailand.
Similar associations were observed for adenocarcinoma/adenosquamous carcinoma, but they were statistically significant only for number of household amenities, parity, and interval since last Pap smear.
The proper evaluation of risk factors other than HPV will require a pooled analysis of all case-control studies that we have carried out or are carrying out in various countries.
The validity or reliability of the assays for HPV DNA detection is critically important in studies on HPV and cervical neoplasia (24, 25) . The PCR-based assay that we have used in our study is considered today to be one of the most reliable (6) . Design limitations should also be considered in the interpretation of our results. Our study was hospital based; as such, it may suffer from selection bias. The case subjects were consecutive incident case subjects attending the largest hospital in Manila, and all agreed to participate. The control subjects were attending the same hospital; therefore, it can be assumed that they came from the same population as the case subjects. However, there were some deviations from the protocol. The control group was intended to have a wide range of diagnoses that were unrelated to the risk factors for cervical carcinoma, but a group of women with benign gynecologic conditions (n ‫ס‬ 53) and a group of healthy women (n ‫ס‬ 57) were included. However, the distribution of the various risk factors in these two groups was similar to that of the rest of the control subjects, and their exclusion from the analysis did not change the risk estimates for HPV and other risk factors. Besides, when we are dealing with ORs of the magnitude found in this study, bias or confounding is very unlikely to explain the very strong associations with the various HPV types.
In conclusion, in the Philippines as in other countries, cervical cancer is a late sequelae of infection with certain types of HPV. Likely cofactors are high parity, smoking, and unidentified factors linked to low socioeconomic status. Cervical cytology screening offers a strong protection.
